PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
48.96%
Net income growth 1.25-1.5x AGEN's 34.31%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.88%
SBC growth while AGEN is negative at -57.80%. John Neff would see competitor possibly controlling share issuance more tightly.
-128.88%
Negative yoy working capital usage while AGEN is 284.39%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-244.33%
Negative yoy AP while AGEN is 70.47%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
1043.06%
Growth well above AGEN's 290.01%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
-114.48%
Both negative yoy, with AGEN at -40.80%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-59.54%
Negative yoy CFO while AGEN is 21.76%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.03%
Debt repayment well below AGEN's 99.87%. Michael Burry suspects heavier leverage risk or insufficient cash generation to keep pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.